Yung-yeh M. Su
Tainan, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: May 10, 2026
Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: May 03, 2026
Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.
Journal: JNCI cancer spectrum
Published: February 09, 2026
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Journal: Liver cancer
Published: February 06, 2026
Reply to: "Comment on "Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration"".
Journal: Journal of hepatology
Published: December 02, 2025
A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 30, 2025
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 18, 2025
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.
Journal: Liver cancer
Published: November 13, 2025
Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.
Journal: Cancer research communications
Published: September 26, 2025
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: June 08, 2025
A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy.
Journal: International journal of surgery (London, England)
Published: April 22, 2025
Last Updated: 09/26/2026